drugset
drugset / Trial / NCT04611789

A Study of LY3832479 (LY-CoV016) in Healthy Participants 1

NCT04611789 ↗

Phase 1 Completed 18 enrolled Eli Lilly and Company Shanghai Junshi Bioscience Co., Ltd. · collab
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to test the safety and tolerability of LY3832479 when it is given by injection just under the skin to healthy participants. Blood tests will be done to check how much LY3832479 is in the bloodstream and how long the body takes to eliminate it. Participation could last up to 16 weeks and may include up to six visits to the study center, with a one-week overnight stay.

Timeline

Start
2020-11-02
Primary completion
2021-02-10
Completion
2021-02-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Etesevimab Monoclonal antibody 350 mg Subcutaneous
Subject Etesevimab Monoclonal antibody 1000 mg Subcutaneous

Indications

No indication recorded.